Swainsonine|72741-87-8|(Tridolgosir)-陌孚医药/Medlife

您当前的位置：

Swainsonine (Synonyms: Tridolgosir)

目录号: PC15220 纯度: ≥98%

CAS No. :72741-87-8

商品编号	规格	价格	会员价
PC15220-500ug	500ug	¥782.04	请登录
PC15220-1mg	1mg	¥1481.76	请登录
PC15220-5mg	5mg	¥6228.88	请登录
PC15220-10mg	10mg	¥10893.68	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Swainsonine

中文别名

苦马豆素;(1S,2R,8R,8AR)-1,2,8-八氢吲哚啶三醇;八倾吲嗪三醇;玛卡提取物;D-苦马豆素;苦马豆素盐酸盐

英文名称

Swainsonine

英文别名

1,2,8-Indolizinetriol,octahydro-, (1S,2R,8R,8aR)-;Swainsonine;(1S,2R,8R,8aR)-octahydro-1,2,8-indolizinetriol;(1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol;8A,B-INDOLIZIDINE-1,2A,8B-TRIOL;D-Swainsonine;SwainMoia;swainsonine synthetic;Tridolgosir;Tridolgosir Hydrochloride;(1S,2R,8R,8aR)-1,2,8-Octahydroindolizidinetriol;(-)-Swainsonine;RSY4RK37KQ;1,2,8-Indolizinetriol, octahydro-, (1S-(1alpha,2alpha,8beta,8abeta))-;1S-8AB-OCTAHYDRO-INDOLIZIDINE-1A,2A,8B-TRIOL;(1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol;Tridolgosir [INN];SWA;Swainosine;Locoweed deriv.;NSC614553;1hww;Octahydro-1,2,8-indolizinetriol

Cas No.

72741-87-8

分子式

C₈H₁₅NO₃

分子量

173.21

包装储存

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Swainsonine (Tridolgosir) is an natural indolizidine alkaloid, a potent and reversible α-mannosidase inhibitor. Swainsonine induces apoptosis and cell cycle arrest at G2/M phase. Swainsonine shows anti-tumor activity.

性状

Solid

体外研究(In Vitro)

Swainsonine (0-40 μM; 12 h) shows antiproliferative activity in U251 and LN444 cells.
Swainsonine (30 μM; 12 h) induces apoptosis and cell cycle arrest at G2/M phase, and decreases the expression of CyclinD1 and CDK4 protein levels, increases the expression of p16 protein level.
Swainsonine (30 μM; 12 h) reduces glioma cell migration and invasion.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	U251, LN444 cells
Concentration:	0, 10, 20, 30, 40 μM
Incubation Time:	12 h
Result:	Inhibited cell viability in a dose-dependent manner, and shows no cytotoxicity in normal brain cells.

Cell Cycle Analysis

Cell Line:	U251 cells
Concentration:	30 μM
Incubation Time:	12 h
Result:	Induced cell cycle arrest at G2/M phase.

Apoptosis Analysis

Cell Line:	U251 cells
Concentration:	30 μM
Incubation Time:	12 h
Result:	Induced apoptosis with the cleaved-Caspase-3 and cleaved-Caspase-9 expression were obviously increased.

体内研究(In Vivo)

Swainsonine (1 mg/kg; i.p.; twice daily for ten days) and cisplatin increases the anti-tumor efficacy in mouse.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eighty-seven sixty-day-old male C57BL/6 mice
Dosage:	1 mg/kg (cisplatin; 0.25 mg/kg, i.p., every other day for 10 days)
Administration:	I.p.; twice daily for ten days
Result:	Showed a significant reduction in ascites volume of 63.5% was observed in mice and a significant reduction in the percentage of cells in the G0/G1, S and G2 phases.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

结构分类

来源

参考文献

[1]. Dorling PR, et al. Inhibition of lysosomal alpha-mannosidase by swainsonine, an indolizidine alkaloid isolated from Swainsona canescens. Biochem J. 1980 Nov 1;191(2):649-51. [Information]

[2]. Sun L, et al. Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression. BMC Cancer. 2019 Mar 19;19(1):247. doi: 10.1186/s12885-019-5425-7. [Information]

[3]. Santos FM, et al. Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. Phytomedicine. 2011 Sep 15;18(12):1096-101. [Information]

溶解度数据

体外研究:

DMSO : 10 mg/mL (57.73 mM; Need ultrasonic and warming)

Ethanol : 10 mg/mL (57.73 mM; Need ultrasonic and warming)

H₂O : 3.57 mg/mL (20.61 mM; ultrasonic and warming and heat to 60°C)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.7733 mL	28.8667 mL	57.7334 mL
5 mM	1.1547 mL	5.7733 mL	11.5467 mL
10 mM	0.5773 mL	2.8867 mL	5.7733 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation